Activation of SARS-CoV-2 by trypsin-like proteases in the clinical specimens of patients with COVID-19

Emiko Yamazaki, Shunsuke Yazawa, Takahisa Shimada, Kosuke Tamura, Yumiko Saga, Masae Itamochi, Noriko Inasaki, Sumiyo Hasegawa, Yoshitomo Morinaga, Kazunori Oishi, Hideki Tani*

*この論文の責任著者

研究成果: ジャーナルへの寄稿学術論文査読

3 被引用数 (Scopus)

抄録

SARS-CoV-2 enters host cells through the angiotensin converting enzyme 2 (ACE2) receptor and/or transmembrane protease, serine 2 (TMPRSS2). In this study, we investigated whether proteases increased SARS-CoV-2 infectivity using pseudotyped viruses and clinical specimens from patients with COVID-19. First, we investigated how trypsin increased infectivity using the pseudotyped virus. Our findings revealed that trypsin increased infectivity after the virus was adsorbed on the cells, but no increase in infectivity was observed when the virus was treated with trypsin. We examined the effect of trypsin on SARS-CoV-2 infection in clinical specimens and found that the infectivity of the SARS-CoV-2 delta variant increased 36,000-fold after trypsin treatment. By contrast, the infectivity of SARS-CoV-2 omicron variant increased to less than 20-fold in the clinical specimens. Finally, using five clinical specimens containing delta variants, enhancement of viral infectivity was evaluated in the presence of the culture supernatant of several anaerobic bacteria. As a result, viral infectivities of all the clinical specimens containing culture supernatants of Fusobacterium necrophorum were significantly increased from several- to tenfold. Because SARS-CoV-2 infectivity increases in the oral cavity, which may contain anaerobic bacteria, keeping the oral cavities clean may help prevent SARS-CoV-2 infection.

本文言語英語
論文番号11632
ジャーナルScientific Reports
13
1
DOI
出版ステータス出版済み - 2023/12

ASJC Scopus 主題領域

  • 一般

フィンガープリント

「Activation of SARS-CoV-2 by trypsin-like proteases in the clinical specimens of patients with COVID-19」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル